Claudio Dansky Ullmann, MD
Chief Medical Officer
Dr. Dansky Ullmann, a 25+-year expert in clinical oncology and pharmaceutical research, is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program. Dr. Dansky Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where, as part of the executive leadership team, he oversaw all clinical development and operations, shaped corporate strategy, and was directly involved in business development activities as well as investor and analyst interactions. Previously, he was a senior medical director and global clinical lead for oncology clinical research in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before joining Takeda, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) as a senior investigator participating in numerous early-phase and late-phase clinical trials. During his career, he also held research roles at the National Institute of Health and held postdoctoral fellowship positions in tumour immunotherapy and drug resistance at the NCI. He also was involved in the development of cell therapies and other immunotherapies at Biomira, Inc. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, University of Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.